These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 32226528)

  • 1. Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1.
    Wilhelmi T; Xu X; Tan X; Hulshoff MS; Maamari S; Sossalla S; Zeisberg M; Zeisberg EM
    Theranostics; 2020; 10(9):3905-3924. PubMed ID: 32226528
    [No Abstract]   [Full Text] [Related]  

  • 2. AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.
    Chow BSM; Kocan M; Shen M; Wang Y; Han L; Chew JY; Wang C; Bosnyak S; Mirabito-Colafella KM; Barsha G; Wigg B; Johnstone EKM; Hossain MA; Pfleger KDG; Denton KM; Widdop RE; Summers RJ; Bathgate RAD; Hewitson TD; Samuel CS
    J Am Soc Nephrol; 2019 Nov; 30(11):2191-2207. PubMed ID: 31511361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-fibrotic actions of relaxin are mediated through AT
    Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS
    FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway.
    Zhou X; Chen X; Cai JJ; Chen LZ; Gong YS; Wang LX; Gao Z; Zhang HQ; Huang WJ; Zhou H
    Drug Des Devel Ther; 2015; 9():4599-611. PubMed ID: 26316699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment.
    Jelinic M; Leo CH; Post Uiterweer ED; Sandow SL; Gooi JH; Wlodek ME; Conrad KP; Parkington H; Tare M; Parry LJ
    FASEB J; 2014 Jan; 28(1):275-87. PubMed ID: 24036884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins.
    Sarwar M; Samuel CS; Bathgate RA; Stewart DR; Summers RJ
    Br J Pharmacol; 2015 Feb; 172(4):1005-19. PubMed ID: 25297987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease.
    Samuel CS; Bodaragama H; Chew JY; Widdop RE; Royce SG; Hewitson TD
    Hypertension; 2014 Aug; 64(2):315-22. PubMed ID: 24866131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crosstalk between endothelial cell-specific calpain inhibition and the endothelial-mesenchymal transition via the HSP90/Akt signaling pathway.
    Sun X; Sun Y; Jiang P; Qi G; Chen X
    Biomed Pharmacother; 2020 Apr; 124():109822. PubMed ID: 31958767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase of cortical cerebral blood flow and further cerebral microcirculatory effects of Serelaxin in a sheep model.
    Bischoff SJ; Schmidt M; Lehmann T; Irintchev A; Schubert H; Jung C; Schwab M; Huber O; Matziolis G; Schiffner R
    Am J Physiol Heart Circ Physiol; 2016 Sep; 311(3):H613-20. PubMed ID: 27402664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered expression of RXFP1 receptor contributes to the inefficacy of relaxin-based anti-fibrotic treatments in systemic sclerosis.
    Corallo C; Pinto AM; Renieri A; Cheleschi S; Fioravanti A; Cutolo M; Soldano S; Nuti R; Giordano N
    Clin Exp Rheumatol; 2019; 37 Suppl 119(4):69-75. PubMed ID: 31365333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells.
    Sarwar M; Samuel CS; Bathgate RA; Stewart DR; Summers RJ
    Br J Pharmacol; 2016 Feb; 173(3):484-96. PubMed ID: 26493539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor-independent modulation of TGF-β-induced pro-fibrotic pathways by relaxin-2 in human primary tubular epithelial cells.
    Grampp S; Goppelt-Struebe M
    Cell Tissue Res; 2018 Dec; 374(3):619-627. PubMed ID: 30078103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serelaxin inhibits differentiation and fibrotic behaviors of cardiac fibroblasts by suppressing ALK-5/Smad2/3 signaling pathway.
    Wu XP; Wang HJ; Wang YL; Shen HR; Tan YZ
    Exp Cell Res; 2018 Jan; 362(1):17-27. PubMed ID: 28987540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. H3 relaxin demonstrates antifibrotic properties via the RXFP1 receptor.
    Hossain MA; Man BC; Zhao C; Xu Q; Du XJ; Wade JD; Samuel CS
    Biochemistry; 2011 Mar; 50(8):1368-75. PubMed ID: 21229994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diosgenin alleviates arsenic trioxide induced cardiac fibrosis by inhibiting endothelial mesenchymal transition.
    Cui H; Xu W; Liu L; Hong Y; Lou H; Tang P; Lin Y; Xu H; Xie M; Du M; Tang X; Wang Z; Wang Q; Zhang Y
    Phytomedicine; 2024 Sep; 132():155891. PubMed ID: 39059093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitriol Attenuates Doxorubicin-Induced Cardiac Dysfunction and Inhibits Endothelial-to-Mesenchymal Transition in Mice.
    Tsai TH; Lin CJ; Hang CL; Chen WY
    Cells; 2019 Aug; 8(8):. PubMed ID: 31405028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology.
    Agoulnik IU; Kaftanovskaya EM; Myhr C; Bathgate RAD; Kocan M; Peng Y; Lindsay RM; DiStefano PS; Agoulnik AI
    Biochem Pharmacol; 2024 Sep; 227():116401. PubMed ID: 38945278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered Cerebral Blood Flow and Potential Neuroprotective Effect of Human Relaxin-2 (Serelaxin) During Hypoxia or Severe Hypovolemia in a Sheep Model.
    Schiffner R; Bischoff SJ; Lehmann T; Irintchev A; Nistor M; Lemke C; Schmidt M
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32120997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human recombinant relaxin-2 does not attenuate hypertension or renal injury but exacerbates vascular dysfunction in a female mouse model of SLE.
    Wolf VL; Phillips TL; Taylor EB; Sasser JM; Ryan MJ
    Am J Physiol Heart Circ Physiol; 2019 Aug; 317(2):H234-H242. PubMed ID: 31125285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relaxin/serelaxin for cardiac dysfunction and heart failure in hypertension.
    Chunduri P; Patel SA; Levick SP
    Adv Pharmacol; 2022; 94():183-211. PubMed ID: 35659372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.